Acquisition taps into the unknown treasures of the sea
Screening for new marine-derived functional ingredients and bringing new patented products to the market.
Earlier this year, Croda, who create, make and sell speciality chemicals for some of the biggest, most successful brands in the world, acquired Nautilus, a marine biotechnology company based at the University of Prince Edward Island, Canada. So, what's in it for Croda?
Why Marine Biotechnology?
Much of the biodiversity on land has been mapped, yet this is not the case for the ocean and freshwater ecosystems that represent more than 70% of the Earth’s surface. Within these unmapped ecosystems, the potential for discovery of biological resources capable of generating a wide variety of materials is huge. Oceanic environments experience the greatest extremes of temperature, light and pressure encountered by life. Adaptation to these harsh environments has led to rich marine bio and genetic diversity with potential biotechnological applications related to drug discovery, environmental remediation and industrial processes.
To date, most marine biotechnology developments have been related to drug discovery. Plans for its use in other industries, however, are also being developed, including materials for cosmetic applications. Studies of extremophiles, micro-organisms found in hostile environments that have developed specific survival mechanisms, have led to the development of novel functional ingredients for the cosmetics industry. Croda already offers a skin care ingredient based on a powerful cocktail of UV and temperature-stable enzymes developed from bacteria that live in hot and highly oxidative deep-sea environments.
Successful Collaboration
Croda and Nautilus already have a proven history of successful collaboration, having worked closely together for the past 6 years developing novel materials for applications in skin care, hair care and crop care. Their collaboration has resulted in the discovery of several novel functional materials that are continuing to be developed for specific applications, such as anti-microbial.
Nautilus will be established as a Croda Centre of Innovation for Marine Biotechnology at their existing base at the University of Prince Edward Island, continuing to also work with the University, where an extensive library of dereplicated marine microbes collected and acquired from various regions of the world can be accessed. The acquisition will allow Croda to screen for new marine-derived functional materials for applications across all its interests and bring new patented products to the market.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance